GlobalData Plc: Oncology Remains at the Forefront of the Companion Diagnostics Industry

Companion diagnostics (CDx) are developed in parallel to the drug using the drug-diagnostic co-development model


LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- Oncology remains the largest segment for FDA-defined marketed drugs with CDx. The FDA has cleared or approved more than 40 CDx in the field of oncology. It is expected that oncology will likely remain the therapeutic area at the forefront of CDx in the future. Although precision medicine encompasses many areas, oncology is the area that is expected to exhibit high growth.

The Companion Diagnostics Thematic Research Report offered by GlobalData Plc looks at the CDx medical devices market and some of the oncology biomarkers, indications, and diagnostic technologies being utilized. The market for biomarker testing continues to increase due to increases in disease, awareness, improved accessibility to personalized medicine, and technological advancements.

Key Companion Diagnostic Technologies

  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Nucleic Acid Amplification (NAAT)
  • Sanger Sequencing
  • Next-Generation Sequencing

Immunohistochemistry is a widely used, antibody-based technique that detects the presence of specific antigens or proteins in tissue. Frequently, chromogenic detection methods are used to visualize antibody-antigen interactions, allowing for the evaluation of cellular localization and staining patterns in the context of tumor structures.

For more detailed insights on CDx technologies, download a free report sample

Key Technology Trends in the CDx Industry

  • Big data
  • Artificial intelligence (AI)
  • Biomarker testing
  • Laboratory developed tests
  • Next-generation sequencing
  • Liquid biopsies

Key Macroeconomic Trends in the CDx Industry

  • Decreasing cost of genetic testing
  • The collaboration between diagnostic and pharmaceutical companies

Key Regulatory Trends in the CDx Industry

  • Impact of clinical guidelines

To get detailed insights on CDx industry trends, download a free report sample

Public Companies Associated with CDx Theme

  • Abbott Laboratories
  • Agilent Technologies
  • bioMerieux
  • Illumina
  • Thermo Fisher Scientific

Private Companies Associated with CDx Theme

  • Asuragen
  • Foundation Medicine
  • MilliporeSigma,
  • Roche Diagnostics International.

To know more about key companies associated with CDx theme, download a free report sample

Companion Diagnostics Market Overview

Key TechnologiesImmunohistochemistry (IHC), In Situ Hybridization (ISH), Nucleic Acid Amplification (NAAT), Sanger Sequencing, and Next-Generation Sequencing
Key Public Companies        Abbott Laboratories, Agilent Technologies, bioMerieux, Illumina, and Thermo Fisher Scientific
Key Private CompaniesAsuragen, Foundation Medicine, MilliporeSigma, and Roche Diagnostics International

Companion Diagnostics Thematic Research Report Scope

  • Identifies those companies most likely to succeed in a world filled with disruptive threats.
  • Predicts how each theme will evolve and identify the leading and disrupting companies.

Reasons to buy

  • GlobalData’s thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. It has a proven track record of identifying the important themes early, enabling companies to make the right investments ahead of the competition, and secure that all-important competitive advantage.
  • Develop and design your corporate strategies through an in-house expert analysis of companion diagnostics by understanding the primary ways in which this theme is impacting the medical devices industry.
  • Stay up to date on the industry’s major players and where they sit in the value chain.
  • Identify emerging industry trends to gain a competitive advantage.

FAQs

What are the key CDx technologies?
The key technologies used in CDx are immunohistochemistry (IHC), in situ hybridization (ISH), nucleic acid amplification (NAAT), and gene sequencing methods such as Sanger sequencing and next-generation sequencing (NGS).

What are the key trends in CDx?
The key trends in CDx are technology trends, macroeconomic trends, and regulatory trends.

Which are the key public companies associated with CDx?
Some of the key public companies associated with CDx are Abbott Laboratories, Agilent Technologies, bioMerieux, Illumina, and Thermo Fisher Scientific.

Which are the key private companies associated with CDx?
Some of the key private companies associated with CDx are Asuragen, Foundation Medicine, MilliporeSigma, and Roche Diagnostics International.

Related reports

  • Banking and Payments Industry Mergers and Acquisitions Deals by Top Themes in Q1 2022 – Thematic ResearchClick here
  • Aerospace, Defence, and Security Industry Mergers and Acquisitions Deals by Top Themes in Q1 2022 – Thematic ResearchClick here
  • Digitalization in Oil and Gas – Thematic ResearchClick here
  • Retail Industry Mergers and Acquisitions Deals by Top Themes in Q1 2022 – Thematic ResearchClick here
  • Cybersecurity – Thematic ResearchClick here

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400